Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Promising Pathways Act (PPA)

<< Previous

Bullboard Posts

Next >>

Comment by Capitalistaon Jul 09, 2023 6:26pm

191 Views

Post# 35532950

RE:Promising Pathways Act (PPA)

The PPA bill could be huge for ONC/Y. I'll have to read the bill to see how it differs from Accelerated Approval (it seems quite similar), but it could not come at a better time for us. Just its introduction will focus more attention on ONC/Y.

I hope that the fractured House can see its way to passing it. The fact that the introduction was bipartisan helps, I think.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments